Pyridostigmine Bromide (Pyridostigmine Bromide) Patent Expiration, LOE Window & CMS Spending
Pyridostigmine Bromide (Pyridostigmine Bromide) by United States Army Office Surgeon General: FDA Orange Book LOE 2038-06-18, 6 AB generics, $25.8M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | United States Army Office Surgeon General |
| FDA Application & Pathway | N020414 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-06-18 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $25.8M |
| 2024 Medicare Part D Spend | $21.6M |
| 2024 Medicaid Spend | $4.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 12.1% 2-yr change) |